Physician profile
Tamara E Tuttle
NPI 1699978601
$730.45
in general payments reported to CMS, 2019-2025
15 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $155 · 2023: $93.92 · 2024: $97.49 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $129.55 | 2024-2025 | |
| Exact Sciences Corporation | $77.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $72.33 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $68.72 | 2021-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $59.48 | 2021-2022 | |
| Lilly USA, LLC | $53.66 | 2021 | |
| Amgen INC. | $48.84 | 2023-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $41.60 | 2023-2024 | Wegovy |
| Mylan Specialty L.P. | $38.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.82 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $34.14 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $28.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2021 | |
| Sanofi Pasteur INC. | $13.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.